Stifel raises GE HealthCare stock price target to $90 on strong Q3

Stifel raised its price target on GE HealthCare (GEHC) to $90 from $80, citing strong Q3 2026 results. The company reported $5.51B in sales, exceeding estimates, with growth across all segments. GEHC raised its full-year guidance and has a record backlog of $23.7B. InvestingPro analysis suggests the stock is undervalued.

Original reporting
Published Oct 28, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The earnings beat and target raise provide a fresh catalyst, likely prompting buying interest.

02

Market read

Strong earnings and an analyst upgrade make GEHC a candidate for short‑term bullish positioning.

03

What to watch

Potential supply‑chain constraints or macro‑economic slowdown could temper growth despite the upbeat report.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

The article summarizes GE HealthCare's Q3 2026 earnings, highlights organic growth, segment performance, and Stifel's upgraded price target.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

Stifel raised its price target on GE HealthCare to $90 after the company reported Q3 sales of $5.51B and raised full-year guidance.

Expected impact

likely upward pressure as investors price in the upgraded target and strong earnings.

Evidence & confidence

The price target increase is a fresh, material analyst action following the earnings release, providing a clear catalyst for short‑term buying.

Market effects

Positive for the health‑care equipment sector as earnings beat may lift peers.

U.S. health‑care stocks could see modest gains.

Limited to investors tracking U.S. health‑care equities.

Counterpoint

The target raise may already be priced in; a pullback could occur if guidance falls short of expectations.

Key entities

  • GE HealthCare

    U.S.-listed health‑care equipment and services provider.

  • Stifel

    Equity research firm that raised the price target.

Related articles

$GEHCMed

GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for feeding tube detection in X-ray imaging. The software supports both adult and pediatric patients, enhancing the company's AI-enabled imaging portfolio. GEHC shares rose 2% post-announcement, with a market cap of $37.51B. The software demonstrated high accuracy in testing, potentially increasing demand for GEHC's mobile imaging systems.

$GEHCMed

GE HealthCare Lands FDA Clearance for On-Device Feeding Tube AI

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for mobile X-ray devices that detects feeding tubes in adults and children. The algorithm, running on-device, achieved 99.2% sensitivity and 91.6% localization accuracy. The company aims to enhance ICU and emergency department workflows, with plans for further AI releases in 2027.

$GEHCMedAI 9/10

GE HealthCare Technologies Inc.: GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, meeting the primary endpoint and showing similar diagnostic preference to gadobutrol. The trial will advance to Phase 3, with mangaciclanol receiving FDA Fast Track designation. GEHC plans to present preliminary results at RSNA 2026.

$GEHCMed

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, advancing it to Phase 3 trials. The agent showed similar diagnostic performance to gadolinium-based agents and was well-tolerated. GEHC aims to address concerns with current contrast agents, such as tissue retention and supply chain issues. The FDA has granted mangaciclanol Fast Track designation.